ICU

Orthogonal Global Group Announces the Appointment of Mona Coyle to the Board of Directors

Retrieved on: 
星期四, 三月 7, 2024

Mrs. Coyle is a Registered Nurse with over a decade of ICU and clinical operations experience.

Key Points: 
  • Mrs. Coyle is a Registered Nurse with over a decade of ICU and clinical operations experience.
  • She has more than 20 years in management and business development, including extensive experience in influencing strategic directions in healthcare.
  • “We are excited to have Mrs. Coyle as the new independent director on the Company’s board of directors.
  • The appointment of Mrs. Coyle follows the resignation of Mr. Mike Grantis from the Board, effective immediately.

ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference

Retrieved on: 
星期五, 三月 1, 2024

SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024.

Key Points: 
  • SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024.
  • ICU Medical’s presentation will be on Monday, March 4, 2024 at 4:30 a.m. PT (7:30 a.m.
  • Company management will also be participating in one-on-one meetings on Monday, March 4, 2024.
  • The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com , clicking on the Investors tab and clicking on the Event Calendar tab.

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

Retrieved on: 
星期二, 二月 27, 2024

Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study.

Key Points: 
  • Approximately 80 sites in the US, Canada, UK and the EU, including Belgium, France, Italy, Germany, Netherlands, Spain and others will conduct the study.
  • The planned primary outcomes are all-cause mortality at Day 28 between treatment groups and incidence, causality, and severity of SAEs in rhu-pGSN vs placebo treatment.
  • Breathing becomes difficult and patients require oxygen, mechanical ventilation and extensive critical care resources, placing a significant burden on the healthcare system.
  • In the U.S. alone, ARDS affects over 700,000 patients per year or roughly 10% of all ICU admissions.

ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance

Retrieved on: 
星期二, 二月 27, 2024

Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year.

Key Points: 
  • Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year.
  • GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same period in the prior year.
  • Adjusted diluted earnings per share for the fourth quarter of 2023 was $1.57 as compared to $1.60 for the fourth quarter of 2022.
  • Also, adjusted EBITDA was $86.3 million for the fourth quarter of 2023 as compared to $96.4 million for the fourth quarter of 2022.

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury

Retrieved on: 
星期四, 二月 22, 2024

DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) Approval Order to the Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) for use in children weighing 10 kilograms or more with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy (KRT). This is the first product in the Company’s newly branded Quelimmune product family, and the Quelimmune pediatric device can now be commercially marketed as a Humanitarian Use Device (HUD).

Key Points: 
  • This is the first product in the Company’s newly branded Quelimmune product family, and the Quelimmune pediatric device can now be commercially marketed as a Humanitarian Use Device (HUD).
  • In clinical studies, Quelimmune for pediatric AKI has been shown to reduce mortality rates and dialysis dependency in clinical studies.
  • “We appreciate the FDA’s willingness to work collaboratively with SeaStar Medical and our advisors to grant HDE approval to Quelimmune for pediatric use,” Mr. Schlorff added.
  • SeaStar Medical is currently focused on its NEUTRALIZE-AKI pivotal clinical trial to evaluate Quelimmune therapy in the larger adult AKI population, while exploring other applications for this device.

Global IV Catheters Market Insights Report 2023-2029: Peripheral Inserted Central Catheters (PICCs) Leading the Charge - ResearchAndMarkets.com

Retrieved on: 
星期五, 二月 23, 2024

The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%

Key Points: 
  • The global IV catheters market was valued at USD 4.93 billion in 2023 and is expected to reach a value of $6.64 billion by 2029, growing at a CAGR of 5.04%
    The global IV catheters market report contains exclusive data on 33 vendors.
  • BD, B Braun, Terumo, Teleflex, ICU Medical, and Nipro Medical are some leading players currently dominating the global IV catheters market.
  • The continuous growth in individuals with chronic conditions and the rapidly expanding elderly population are the primary factors fueling the global demand for peripheral IV catheters.
  • The peripheral inserted central catheters (PICCs) product segment accounted for the highest market share of over 45% of the global CIVCs market.

CEO Club Hosts Successful AI Conference Featuring Prominent Industry Leaders

Retrieved on: 
星期五, 三月 8, 2024

LONDON, March 8, 2024 /PRNewswire/ -- The CEO Club proudly hosted an engaging AI conference on February 27th, bringing together esteemed experts and industry leaders to delve into the present and future of artificial intelligence (AI).

Key Points: 
  • LONDON, March 8, 2024 /PRNewswire/ -- The CEO Club proudly hosted an engaging AI conference on February 27th, bringing together esteemed experts and industry leaders to delve into the present and future of artificial intelligence (AI).
  • The conference commenced with a riveting Keynote Address titled "AI: Our Present and What the Future Promises?"
  • Guests in attendance included CEO Club members, business representatives, founders, and diplomats, all of whom actively participated in the enriching dialogue and networking opportunities provided by the conference.
  • The CEO Club extends its gratitude to all participants, speakers, and members for their contributions to the success of the AI conference.

THE CENTER FOR DISCOVERY NAMES DONALD W. LANDRY, MD, PHD AS NEW BOARD MEMBER

Retrieved on: 
星期五, 三月 1, 2024

HARRIS, N.Y., March 1, 2024 /PRNewswire/ -- The Center for Discovery® (TCFD) today announced that Donald W. Landry, MD, PhD, has been elected to its Board of Directors. His appointment is effective March 1st, 2024.

Key Points: 
  • HARRIS, N.Y., March 1, 2024 /PRNewswire/ -- The Center for Discovery® (TCFD) today announced that Donald W. Landry, MD, PhD, has been elected to its Board of Directors .
  • "Together, our Board of Directors – leaders in their respective industries – provide an invaluable scope of services to The Center.
  • "The vibrant spirit of The Center for Discovery radiates in the persons it serves, its devoted staff and its inspired leadership.
  • I am delighted, and deeply humbled, to join The Board of the Center for Discovery," said Dr. Landry.

Health Catalyst Announces Winners of the 2024 Catalyst Awards

Retrieved on: 
星期四, 二月 29, 2024

SALT LAKE CITY, Feb. 29, 2024 /PRNewswire/ -- Today, Health Catalyst publicly announced the seven winners of the Catalyst Awards, an annual awards program recognizing hospitals and health systems that have led the way in digitizing and transforming healthcare.

Key Points: 
  • SALT LAKE CITY, Feb. 29, 2024 /PRNewswire/ -- Today, Health Catalyst publicly announced the seven winners of the Catalyst Awards, an annual awards program recognizing hospitals and health systems that have led the way in digitizing and transforming healthcare.
  • The winners were announced at the annual Healthcare Analytics Summit (HAS) in Salt Lake City, Utah.
  • Without this work, the health system would have needed inpatient beds for 10 more patients every day of the year.
  • "We're proud to recognize these seven organizations for their incredible data-driven healthcare transformation," said Dan Burton, CEO of Health Catalyst.

MNA: BI Anna Jaques Hospital RNs Vote to Ratify New Three-Year Contract to Recruit and Retain the Staff Needed to Ensure Quality Patient Care

Retrieved on: 
星期二, 二月 27, 2024

The contract agreement followed more than six months of negotiations and will cover 350 registered nurses who work at the Newburyport-based facility.

Key Points: 
  • The contract agreement followed more than six months of negotiations and will cover 350 registered nurses who work at the Newburyport-based facility.
  • This could never have happened if we didn't have the support, encouragement, and participation of our 350 nurses.
  • During this time, we also have been fortified by the support from all hospital caregivers and our community.
  • The common theme between hospital staff members and the community is that we all care about our hospital, and we all share a willingness to work to make it stronger."